Published • loading... • Updated
Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)
Professor Cheng Zhou presented efficacy and safety data for the topical combination, which showed significant improvement in a Phase 2 study, the company said.
- At the 14th World Congress for Hair Research in Seoul, South Korea, Professor Cheng Zhou presented positive Phase 2 results for CG2001, a topical combination of minoxidil and finasteride for androgenetic alopecia.
- CG2001 utilizes a proprietary foam delivery system to combine minoxidil, which promotes hair growth, and finasteride, which inhibits 5-alpha-reductase, optimizing local follicular delivery and efficacy.
- Twice-Daily application of CG2001 demonstrated a statistically significant improvement in Target Hair Count compared to placebo, outperforming the control group in the Phase 2 trial.
- The study found CG2001 was generally well-tolerated across all treatment groups, with adverse events categorized as mild to moderate, supporting differentiation in the dermatology market.
- Dayspring Pharma is currently engaging with regulatory authorities to define the next phase of clinical development, with CEO Baohui Xu emphasizing the company's commitment to continued advancement.
Insights by Ground AI
40 Articles
40 Articles
LoudounTimes.com+39 Reposted by 39 other sources
Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)
SEOUL, South Korea, June 7, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of positive topline results from its Phase II randomized, double-blind, placebo-controlled trial of CG2001 at the…
Coverage Details
Total News Sources40
Leaning Left4Leaning Right5Center14Last UpdatedBias Distribution61% Center
Bias Distribution
- 61% of the sources are Center
61% Center
L 17%
C 61%
R 22%
Factuality
To view factuality data please Upgrade to Premium
